Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab With Curettage and Repair for Perianal Fistulizing Crohn's Disease
NCT07782021Phase 4Not yet recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mirikizumab in Crohn's disease and perianal fistula, sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Proportion of participants achieving combined clinical remission and radiologic response at 24 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's diseaseperianal fistula
Beyond the preview
Go deeper on NCT07782021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782021.